Papers/PMID:26066335
Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.
Journal of clinical psychopharmacology2015The record
3 findings drawn from this paper, on 1 compound across 3 endpoints.
What it reported
How to read these marksWhat moved
3 findings
curcumin — decreases hamilton Depression Rating Scale (HDRS) total score
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Finding“Chronic supplementation with curcumin produced significant antidepressant behavioral response in depressed patients by reduction of 17-item Hamilton Depression Rating Scale and Montgomery-Asberg Depression Rating Scale scores.”
Quoted verbatim from Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.. - Study
- RCT
- Duration
- 6 weeks
- Dose
- 1000 mg/day (2 capsules)
- Population
- adult men (31-59 years) with major depressive disorder, continuing their existing antidepressant medication regimen in both curcumin and placebo arms (adjunctive therapy)
curcumin — decreases tumour necrosis factor alpha concentration
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Findingreplicated ×5“Furthermore, curcumin decreases inflammatory cytokines interleukin 1β and tumor necrosis factor α level, increases plasma brain-derived neurotrophic factor levels, and decreases salivary cortisol concentrations compared with placebo group.”
Quoted verbatim from Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.. - Study
- RCT
- Duration
- 6 weeks
- Dose
- 1000 mg/day (2 capsules)
- Population
- adult men (31-59 years) with major depressive disorder, continuing their existing antidepressant medication regimen in both curcumin and placebo arms (adjunctive therapy)
curcumin — decreases cortisol concentration
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Finding“Furthermore, curcumin decreases inflammatory cytokines interleukin 1β and tumor necrosis factor α level, increases plasma brain-derived neurotrophic factor levels, and decreases salivary cortisol concentrations compared with placebo group.”
Quoted verbatim from Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.. - Study
- RCT
- Duration
- 6 weeks
- Dose
- 1000 mg/day (2 capsules)
- Population
- adult men (31-59 years) with major depressive disorder, continuing their existing antidepressant medication regimen in both curcumin and placebo arms (adjunctive therapy)